JP2013545779A5 - - Google Patents

Download PDF

Info

Publication number
JP2013545779A5
JP2013545779A5 JP2013543710A JP2013543710A JP2013545779A5 JP 2013545779 A5 JP2013545779 A5 JP 2013545779A5 JP 2013543710 A JP2013543710 A JP 2013543710A JP 2013543710 A JP2013543710 A JP 2013543710A JP 2013545779 A5 JP2013545779 A5 JP 2013545779A5
Authority
JP
Japan
Prior art keywords
amino
imidazo
cyclopropyl
pyrazin
benzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013543710A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013545779A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/072591 external-priority patent/WO2012080236A1/en
Publication of JP2013545779A publication Critical patent/JP2013545779A/ja
Publication of JP2013545779A5 publication Critical patent/JP2013545779A5/ja
Pending legal-status Critical Current

Links

JP2013543710A 2010-12-17 2011-12-13 過剰増殖性障害の治療におけるmps−1およびtkk阻害剤として使用するための6置換イミダゾピラジン Pending JP2013545779A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP10195635.7 2010-12-17
EP10195699 2010-12-17
EP10195635 2010-12-17
EP10195699.3 2010-12-17
EP11170158.7 2011-06-16
EP11170158 2011-06-16
EP11170163 2011-06-16
EP11170163.7 2011-06-16
PCT/EP2011/072591 WO2012080236A1 (en) 2010-12-17 2011-12-13 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders

Publications (2)

Publication Number Publication Date
JP2013545779A JP2013545779A (ja) 2013-12-26
JP2013545779A5 true JP2013545779A5 (cg-RX-API-DMAC7.html) 2015-02-05

Family

ID=45218758

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013543710A Pending JP2013545779A (ja) 2010-12-17 2011-12-13 過剰増殖性障害の治療におけるmps−1およびtkk阻害剤として使用するための6置換イミダゾピラジン

Country Status (6)

Country Link
US (1) US20140135319A1 (cg-RX-API-DMAC7.html)
EP (1) EP2651945A1 (cg-RX-API-DMAC7.html)
JP (1) JP2013545779A (cg-RX-API-DMAC7.html)
CN (1) CN103429592A (cg-RX-API-DMAC7.html)
CA (1) CA2821819A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012080236A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60100852A (ja) * 1984-09-28 1985-06-04 Hitachi Ltd 情報伝送方法
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
GB201212513D0 (en) * 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
EP2920181B1 (en) 2012-11-16 2019-01-09 University Health Network Pyrazolopyrimidine compounds
US9376441B2 (en) * 2013-07-31 2016-06-28 Gilead Sciences, Inc. Substituted pyrrolidines as SYK inhibitors
JP6095857B2 (ja) * 2013-11-15 2017-03-15 ユニバーシティ・ヘルス・ネットワーク ピラゾロピリミジン化合物
US9493442B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
JP6602779B2 (ja) 2014-02-13 2019-11-06 インサイト・コーポレイション Lsd1阻害剤としてのシクロプロピルアミン類
CN106164066B (zh) 2014-02-13 2020-01-17 因赛特公司 作为lsd1抑制剂的环丙胺
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
CN107660205B (zh) 2015-04-03 2021-08-27 因赛特公司 作为lsd1抑制剂的杂环化合物
AU2016247476B2 (en) 2015-04-17 2021-12-16 SillaJen Inc. Prognostic biomarkers for TTK inhibitor chemotherapy
EA035534B1 (ru) 2015-08-12 2020-06-30 Инсайт Корпорейшн Соли ингибитора lsd1
BR112018071585B1 (pt) 2016-04-22 2024-01-02 Incyte Corporation Formulações de um inibidor de lsd1, seus usos e método de preparação das mesmas
IL293956A (en) 2017-04-12 2022-08-01 Magenta Therapeutics Inc Aryl hydrocarbon receptor antagonist and its uses
CA3079405A1 (en) * 2017-10-31 2019-05-09 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells
HRP20241414T1 (hr) * 2018-05-08 2024-12-20 Nippon Shinyaku Co., Ltd. Azabenzimidazolski spojevi i farmaceutski proizvod
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
US20210379033A1 (en) * 2018-10-17 2021-12-09 Magenta Therapeutics Inc. Methods of treating cancer with aryl hydrocarbon receptor antagonists

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
MXPA05003120A (es) * 2002-09-23 2005-06-22 Schering Corp Imidazopirazinas como inhibidores de cinasa dependientes de ciclinas.
KR20060010709A (ko) * 2002-09-23 2006-02-02 쉐링 코포레이션 사이클린 의존성 키나제 억제제로서의 신규한 이미다조피라진
US7576085B2 (en) * 2002-09-23 2009-08-18 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
US7157460B2 (en) * 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7186832B2 (en) 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
WO2007032936A2 (en) * 2005-09-09 2007-03-22 Schering Corporation Azafused cyclin dependent kinase inhibitors
US20070117804A1 (en) 2005-11-10 2007-05-24 Schering Corporation Imidazopyrazines as protein kinase inhibitors
US20070105864A1 (en) * 2005-11-10 2007-05-10 Schering Corporation Methods for inhibiting protein kinases
TW200808802A (en) 2006-06-06 2008-02-16 Schering Corp Imidazopyrazines as protein kinase inhibitors
EP2063882A4 (en) * 2006-09-05 2010-03-03 Univ Emory TYROSINKINASE INHIBITOR FOR PREVENTING OR TREATING INFECTIONS
JP2010509328A (ja) * 2006-11-08 2010-03-25 シェーリング コーポレイション プロテインキナーゼの阻害剤としてのイミダゾピラジン
GB0716292D0 (en) * 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
US20110118238A1 (en) * 2007-08-23 2011-05-19 Astrazeneca Ab 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders
CA2760077A1 (en) 2009-04-29 2010-11-04 Marcus Koppitz Substituted imidazoquinoxalines
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
WO2011026579A1 (en) 2009-09-04 2011-03-10 Bayer Schering Pharma Aktiengesellschaft Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343295A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
ES2551407T3 (es) * 2010-03-18 2015-11-18 Bayer Intellectual Property Gmbh Imidazopirazinas
ES2555261T3 (es) * 2010-06-01 2015-12-30 Bayer Intellectual Property Gmbh Imidazopirazinas sustituidas
CN103443100B (zh) * 2010-12-17 2016-03-23 拜耳知识产权有限责任公司 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的取代的6-咪唑并吡嗪
EP2651947B1 (en) * 2010-12-17 2014-12-10 Bayer Intellectual Property GmbH 6-thio-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
WO2012080230A1 (en) * 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders

Similar Documents

Publication Publication Date Title
JP2013545779A5 (cg-RX-API-DMAC7.html)
JP2013515729A5 (cg-RX-API-DMAC7.html)
HRP20201337T1 (hr) Inhibitori lizin-specifične demetilaze-1
JP2013537174A5 (cg-RX-API-DMAC7.html)
JP2016523911A5 (cg-RX-API-DMAC7.html)
RU2507204C2 (ru) Положительные аллостерические модуляторы м1-рецепторов на основе пираниларилметилбензохиназолинона
CN111601593B (zh) P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd
SI3083586T1 (en) The new carboxamides, the process of their manufacture, the pharmaceutical preparations they contain and their use for the manufacture of medicinal products
HRP20240994T1 (hr) Spoj inhibitora jak i njegova uporaba
SI3183247T1 (en) Aminopyrimidinyl compounds as inhibitors of JAK
JP2006520805A5 (cg-RX-API-DMAC7.html)
JP2019504821A5 (cg-RX-API-DMAC7.html)
RU2016124176A (ru) Композиции тетрагидрохинолинов в качестве ингибиторов бромодомена вет
JP2011520908A5 (cg-RX-API-DMAC7.html)
HRP20160360T1 (hr) Supstituirani imidazopiridazini
JP2016528298A5 (cg-RX-API-DMAC7.html)
JP2014521711A5 (cg-RX-API-DMAC7.html)
JP2013523884A5 (cg-RX-API-DMAC7.html)
RU2015152576A (ru) Производные индолин-2-она или пирролопиридин/пиримидин-2-она
JP2012501312A5 (cg-RX-API-DMAC7.html)
JP2011506417A5 (cg-RX-API-DMAC7.html)
JP2014522855A5 (cg-RX-API-DMAC7.html)
JP2017505794A5 (cg-RX-API-DMAC7.html)
JP2014501269A5 (cg-RX-API-DMAC7.html)
JP2015500332A5 (cg-RX-API-DMAC7.html)